GLAXO HOPES TO ADAPT MEASLES SHOT FOR HIV

GlaxoSmithKline plans to develop an experimental AIDS vaccine by "piggy-backing" on a shot against measles. Europe's biggest drug maker and France's Institut Pasteur intend to make the vaccine by fusing genes from the human immunodeficiency virus ( HIV ) onto an existing vaccine for the childhood disease, the two organizations said on Monday. GSK Biologicals -- Glaxo's vaccines unit -- will license the measles vaccine vector, or carrier, technology from Institut Pasteur, and researchers from both groups will jointly develop the new vaccine.

Leading the Charge (http://www.leadingthecharge.com/stories/news-00105435.html)